# SPECIALTY GUIDELINE MANAGEMENT

# APOKYN (apomorphine)

## POLICY

### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

# **FDA-Approved Indication**

Acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced Parkinson's disease.

All other indications are considered experimental/investigational and are not a covered benefit.

### **II. CRITERIA FOR APPROVAL**

Authorization of 12 months may be granted for the treatment of acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) for members with advanced Parkinson's disease.

# **III. CONTINUATION OF THERAPY**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

### **IV. REFERENCES**

1. Apokyn [package insert]. Louisville, KY: US WorldMeds, LLC; July 2014.

Apokyn SGM P2017a

© 2017 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

